sentences:  (now UCB S.A.) and was a putative new drug for oral treatment of multiple sclerosis.In October 2006, UCB and Biogen Idec announced a collaboration to jointly develop and commercialize zaurategrast for the treatment of multiple sclerosis and other potential indications.In June 2009, development of zaurategrast was discontinued due to discouraging results of a Phase II clinical trial.